ReviewDrug design, development and therapy2018

Copanlisib for treatment of B-cell malignancies: the development of a PI3K inhibitor with considerable differences to idelalisib.

Günter Krause et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.